Truist analyst Richard Newitter has reduced the price target for Vericel (VCEL, Financial) from $61 to $51, maintaining a Buy rating on the stock. This adjustment comes as part of a broader analysis of the medical technology sector in anticipation of the first quarter results.
Despite some expected tariff-related instability, the medical technology sector remains comparatively resilient in its revenue and earnings potential. This stability is likely to sustain investor interest, even amid broad market uncertainties. However, the analyst notes that companies are bracing for 2025 with caution, factoring in potential macroeconomic challenges into their projections and strategic models.
Investors and stakeholders should anticipate careful guidance and outlooks as companies prepare to navigate these uncertainties, potentially impacting future performance and market positioning.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Vericel Corp (VCEL, Financial) is $65.38 with a high estimate of $72.00 and a low estimate of $60.00. The average target implies an upside of 55.80% from the current price of $41.96. More detailed estimate data can be found on the Vericel Corp (VCEL) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Vericel Corp's (VCEL, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Vericel Corp (VCEL, Financial) in one year is $47.83, suggesting a upside of 13.99% from the current price of $41.96. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Vericel Corp (VCEL) Summary page.
